A French retrospective analysis reports real-world evidence for venetoclax in Waldenström macroglobulinemia, focusing on patients with disease return after standard treatments. The work indicates improved depth of response when venetoclax is paired with an antibody, showing a clear direction for combination therapy in this hard-to-treat setting. The report characterizes the data as among the most detailed real-world assessments available for this patient population and scenario. Importantly, it frames the findings as evidence supporting a combination approach rather than venetoclax monotherapy. For hematology teams, the relevance is immediate: treatment sequencing and regimen selection are often constrained in relapsed Waldenström, and real-world response depth can influence practice patterns ahead of prospective comparisons. The combined regimen also reinforces the broader strategy of layering targeted agents with immune engagement to extend benefit when durability is uncertain.